Drugs. ;68(12) Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. Indications, side effects, contraindications and other prescribing information for Durogesic DTrans on MIMS. Following an abbreviated submission. transdermal fentanyl (Durogesic D Trans patches) 12 mcg/hour is accepted for restricted use within NHS.
|Published (Last):||10 December 2016|
|PDF File Size:||14.52 Mb|
|ePub File Size:||13.4 Mb|
|Price:||Free* [*Free Regsitration Required]|
Severe and unpredictable interactions with MAOIs, involving the potentiation of opiate effects or the potentiation of serotoninergic effects, have been reported.
Durogesic DTrans | MIMS online
Careful monitoring should be continued until stable drug effects are achieved. Fold the patch in the middle and remove each half of the liner separately. If patients with hepatic impairment receive Durogesic DTrans, they should be observed carefully for signs durageaic fentanyl toxicity and the dose of Durogesic DTrans reduced if necessary see section 5. Published 11 December V-trans, physical dependence, and psychological dependence may develop upon repeated administration of opioids.
Thank you for your feedback. Patients and their carers must be instructed that Durogesic DTrans contains an active substance in an amount that can be fatal, especially to a child. The leaflet has recently been redesigned to clarify the posology for these patches and uses good navigation tools.
Breastfeeding dtrans therefore be discontinued during treatment with Durogesic DTrans and for at least 72 hours after removal of the patch. Effects on the embryo were due to maternal toxicity and not to direct effects of the substance on the developing embryo.
Initial evaluation of the maximum analgesic effect of Durogesic DTrans cannot be made before the patch is worn for 24 hours. Apply the patch to the skin by applying light pressure with the palm of the hand for about 30 seconds. Patients should be advised that if accidental patch transfer occurs, the transferred patch must be removed immediately from the skin of the non-patch wearer see section 4.
Adequate body temperature and fluid intake should be maintained. Durogesic DTrans should be administered only to opioid-tolerant children age 2 years or older see section 4. The conversion schedule should not be used to convert from Durogesic DTrans into other opioids, as overdosing could then occur.
High inter-subject variability in plasma concentrations has been observed.
You will be re-directed back to this page where you will have the ability to comment. Opioid withdrawal symptoms such as nausea, vomiting, diarrhoea, anxiety, and shivering are possible in some patients after conversion from their previous opioid analgesic to Durogesic DTrans or if therapy is stopped suddenly see section 4. Fentanyl is a high clearance active substance and is rapidly and extensively metabolised primarily by CYP3A4 in the liver.
Fentanyl then becomes available to the systemic circulation.
Durogesic DTrans 12 mcg/hr Transdermal Patch
Durogesic DTrans should be used with caution in patients with brain tumours. Several days should elapse before a new patch is applied to the same area of the skin.
It will take only 2 minutes dugagesic fill in. Physicochemical Principles of Pharmacy This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body. Accidental transfer of a fentanyl patch to the skin of a non-patch duraesic particularly a childwhile sharing a bed or being in close physical contact with a patch wearer, may result in an opioid overdose for the non-patch wearer.
Durogesic DTrans 12 mcg/hr Transdermal Patch – Summary of Product Characteristics (SmPC) – (eMC)
Anaphylactic shock, Anaphylactic reaction, Anaphylactoid reaction. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Table 3 is for adult patients who are on a stable, and well-tolerated, opioid regimen conversion ratio of oral morphine to transdermal fentanyl approximately equal to The tendency of tolerance development varies widely among individuals.
Drug dependence and potential for abuse Tolerance, physical dependence, and psychological dependence may develop upon repeated administration of opioids.
Caution is advised when Durogesic DTrans is co-administered with medicinal products that affect the serotonergic neurotransmitter systems.
PIL of the month: Durogesic D Trans Transdermal Patch
Enter email address Submit. Marketing authorisation number s 9. Convert this amount to the equianalgesic hour oral morphine dose using the multiplication factors in Table 1 for the appropriate route of administration. A Guide for Dkragesic Dosing. All patients should be advised to avoid exposing the Durogesic DTrans application site to direct external heat sources such as heating pads, electric blankets, heated water beds, heat or tanning lamps, sunbathing, hot water bottles, prolonged hot baths, saunas and hot whirlpool spa baths.
In patients currently taking opioid analgesics, the starting dose of Durogesic DTrans should be based on the daily dose of the prior opioid. Respiratory, thoracic and mediastinal disorders. Ear and labyrinth disorders.